---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-091733"
form_type: "8-K"
ticker: "ACXP"
cik: "0001736243"
company_name: "Acurx Pharmaceuticals, Inc."
filed_at: "2025-09-19T23:59:59+00:00"
generated_at: "2026-05-17T06:07:34.107206+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Acurx shareholders approve warrant exercise and authorized share increase at special meeting

## Summary
- Proposal 1 (warrant exercise for Nasdaq compliance): 8,816,581 for, 602,155 against, 9,823,429 broker non-votes.
- Proposal 2 (authorized share increase 200M to 250M): 16,476,460 for, 2,526,119 against, 363,000 abstentions.
- Proposal 3 (adjournment) approved: 16,538,163 for, 2,271,234 against, 556,182 abstentions.
- Quorum: 19,365,579 shares (63.44%) of 30,524,540 outstanding shares represented.

## SEC filing metadata
- accession: 0001104659-25-091733
- form_type: 8-K
- ticker: ACXP
- cik: 0001736243
- company_name: Acurx Pharmaceuticals, Inc.
- filed_at: 2025-09-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1736243/000110465925091733/0001104659-25-091733-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1736243/000110465925091733/tm2526531d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-091733
- JSON: https://secwatch.observer/filing/0001104659-25-091733.json
- Plain text: https://secwatch.observer/filing/0001104659-25-091733.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.